Wave Life Sciences Pte. Ltd. (NASDAQ:WVE) was the target of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 879,205 shares, a growth of 64.6% from the October 14th total of 534,211 shares. Approximately 7.2% of the company’s stock are short sold. Based on an average daily trading volume, of 52,162 shares, the short-interest ratio is presently 16.9 days.

A number of institutional investors have recently modified their holdings of WVE. Wells Fargo & Company MN purchased a new position in shares of Wave Life Sciences Pte. during the third quarter valued at approximately $136,000. BlackRock Advisors LLC increased its position in shares of Wave Life Sciences Pte. by 67.6% in the third quarter. BlackRock Advisors LLC now owns 4,264 shares of the company’s stock valued at $138,000 after buying an additional 1,720 shares during the last quarter. Strs Ohio purchased a new position in shares of Wave Life Sciences Pte. during the third quarter valued at approximately $194,000. Lesa Sroufe & Co purchased a new position in shares of Wave Life Sciences Pte. during the third quarter valued at approximately $209,000. Finally, Teachers Advisors Inc. purchased a new position in shares of Wave Life Sciences Pte. during the second quarter valued at approximately $246,000. Institutional investors own 60.62% of the company’s stock.

WVE has been the subject of several research analyst reports. JMP Securities restated a “buy” rating on shares of Wave Life Sciences Pte. in a report on Thursday. Jefferies Group set a $28.00 price objective on shares of Wave Life Sciences Pte. and gave the stock a “buy” rating in a report on Monday, August 15th. Zacks Investment Research upgraded shares of Wave Life Sciences Pte. from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th. Finally, Leerink Swann restated an “outperform” rating and issued a $28.00 price objective (up from $20.00) on shares of Wave Life Sciences Pte. in a report on Tuesday, August 16th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $30.80.

Wave Life Sciences Pte. (NASDAQ:WVE) opened at 36.50 on Friday. The stock’s 50 day moving average is $31.75 and its 200 day moving average is $22.92. The stock’s market capitalization is $855.56 million. Wave Life Sciences Pte. has a 12-month low of $8.95 and a 12-month high of $38.50.

Wave Life Sciences Pte. (NASDAQ:WVE) last posted its earnings results on Monday, August 15th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.14. Equities analysts predict that Wave Life Sciences Pte. will post ($2.17) earnings per share for the current fiscal year.

Wave Life Sciences Pte. Company Profile

WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

5 Day Chart for NASDAQ:WVE

Receive News & Stock Ratings for Wave Life Sciences Pte. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences Pte. Ltd. and related stocks with our FREE daily email newsletter.